Zobrazeno 1 - 10
of 36
pro vyhledávání: '"G M, Kenny"'
Publikováno v:
The Prostate. 43(1)
Infusion of dendritic cells (DCs) pulsed with PSMA peptides was considered possible in hormone-refractory metastatic prostate cancer patients both with or without prior treatment with a greater number of DCs and for lesser infusions than previously a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a83022fdd75da32344e2d435bbcabfd0
https://pubmed.ncbi.nlm.nih.gov/10725866
https://pubmed.ncbi.nlm.nih.gov/10725866
Publikováno v:
The Prostate. 42(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8af6c88b2750dcec128bcbf6dc78de34
https://pubmed.ncbi.nlm.nih.gov/10679762
https://pubmed.ncbi.nlm.nih.gov/10679762
Publikováno v:
The Prostate. 42(4)
A reliable imaging modality is required to uncover occult soft- tissue recurrence after failure of primary prostate cancer therapy. This retrospective study was done to evaluate the ability of the (111)Indium-labeled monoclonal antibody (ProstaScint(
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d98336ebacfdc3d0100d822cbc67430
https://pubmed.ncbi.nlm.nih.gov/10679761
https://pubmed.ncbi.nlm.nih.gov/10679761
Autor:
B A, Tjoa, S J, Simmons, A, Elgamal, M, Rogers, H, Ragde, G M, Kenny, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 40(2)
A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::db213d69aeaa4f93ae3a065a1b762c98
https://pubmed.ncbi.nlm.nih.gov/10386473
https://pubmed.ncbi.nlm.nih.gov/10386473
Autor:
S J, Simmons, B A, Tjoa, M, Rogers, A, Elgamal, G M, Kenny, H, Ragde, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 39(4)
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulsed with HLA-A2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa05b31019e37805f850a84285790712
https://pubmed.ncbi.nlm.nih.gov/10344219
https://pubmed.ncbi.nlm.nih.gov/10344219
Autor:
G P, Murphy, B A, Tjoa, S J, Simmons, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, M J, Troychak, M L, Salgaller, A L, Boynton
Publikováno v:
The Prostate. 39(1)
A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects admitted with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfc6a98ff073f2f5c17297b6478368a8
https://pubmed.ncbi.nlm.nih.gov/10221267
https://pubmed.ncbi.nlm.nih.gov/10221267
Autor:
G P, Murphy, B A, Tjoa, S J, Simmons, J, Jarisch, V A, Bowes, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, M L, Salgaller, A L, Boynton
Publikováno v:
The Prostate. 38(1)
A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate cancer without
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1a7de4d21eeceb59cbb048032a40811b
https://pubmed.ncbi.nlm.nih.gov/9973112
https://pubmed.ncbi.nlm.nih.gov/9973112
Autor:
B A, Tjoa, S J, Simmons, V A, Bowes, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, M L, Salgaller, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 36(1)
A phase I trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (DC) and HLA-A0201-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 or -P2). Thirty-three of the ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e365ee2b871ecf56e9ba6ba60eaf3a4
https://pubmed.ncbi.nlm.nih.gov/9650914
https://pubmed.ncbi.nlm.nih.gov/9650914
Autor:
M L, Salgaller, P A, Lodge, J G, McLean, B A, Tjoa, D J, Loftus, H, Ragde, G M, Kenny, M, Rogers, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 35(2)
In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings.Phase II subjects received six
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b427b5341542a3bb1915deaa1e3fe25a
https://pubmed.ncbi.nlm.nih.gov/9568678
https://pubmed.ncbi.nlm.nih.gov/9568678
Autor:
G P, Murphy, R T, Maguire, B, Rogers, A W, Partin, W B, Nelp, M J, Troychak, H, Ragde, G M, Kenny, R J, Barren, V A, Bowes, A K, Gregorakis, E H, Holmes, A L, Boynton
Publikováno v:
The Prostate. 33(4)
Stored serum from clinical trial cases undergoing ProstaScint (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opportunity to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::99f8ec25c85dcfb8d9874cbe12094705
https://pubmed.ncbi.nlm.nih.gov/9397201
https://pubmed.ncbi.nlm.nih.gov/9397201